MTOR and acute myeloid leukemia: Also, the interaction with stromal cells increases the glycolytic flux of AML cells from patients through the CXCR4/CXCL12/mTOR axis (Braun et al., 2016), and the use of selective inhibitors of this axis represents an opportunity to block MSC-mediated chemoresistance (Braun et al., 2016).